Cardiac complications of chemotherapy: role of imaging.
Cardiac complications of chemotherapy: role of imaging.
复制标题
DOI：
10.1007/s11936-014-0296-3
复制
发表时间：
2014-04-01
影响因子：
--
通讯作者：
Scherrer-Crosbie, Marielle
中科院分区：
文献类型：
--
作者：
Tan, Timothy C;Scherrer-Crosbie, Marielle
观点声明：癌症诊断和治疗的新进展提高了癌症患者的生存率。与癌症幸存者人数增加的同时，癌症治疗引起的心脏并发症的患病率也在增加。化疗引起的心功能不全是癌症患者不良发病率和死亡率的主要原因。有证据表明，临床症状和传统的左心室射血分数（LVEF）可能缺乏敏感性作为心脏毒性的措施。亚临床LV功能障碍的早期识别变得越来越重要，因为这可以使癌症患者及其医生做出关于治疗选择的明智决定。超声心动图的特点使其成为诊断和监测心脏毒性的有用工具。本综述将研究心脏成像在检测心脏毒性中的作用，主要关注评估亚临床心脏毒性的传统和最新超声心动图方法。
OPINION STATEMENT: New advances in cancer diagnosis and treatment have increased survival rates in patients with cancer. In parallel with this increase in the number of cancer survivors is an increasing prevalence of cardiac complications from cancer treatment. Chemotherapy-induced cardiac dysfunction is a major contributor to adverse morbidity and mortality rates in cancer patients. Evidence suggests that both clinical symptoms and the traditional left ventricular ejection fraction (LVEF) may lack sensitivity as measures of cardiotoxicity. The early identification of subclinical LV dysfunction is becoming increasingly important, as this may allow cancer patients and their physicians to make informed decisions about therapeutic options. The features of echocardiography make it a useful tool in the diagnosis and monitoring of cardiotoxicity. This review will examine the role of cardiac imaging in detecting cardiotoxicity, focusing primarily on the conventional and more recent echocardiographic approaches for assessing subclinical cardiotoxicity.